Rosenstock 2023 — Retatrutide Phase 2 T2D

Lancet·June 26, 2023

Rosenstock J, et al.

Summary

Triple agonist showed significant HbA1c reductions and weight loss in patients with type 2 diabetes.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled dose-finding trial

Indication

Type 2 diabetes

Intervention

Retatrutide (GLP-1/GIP/glucagon triple agonist) vs placebo

Species

Human

Sample Size

281 subjects

Risk of Bias Assessment

Lilly-sponsored